Portfolio company
Atsena
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage gene therapy company develops genetic medicines to reverse or prevent blindness for patients with inherited retinal diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Atsena Therapeutics
This clinical-stage company develops gene therapies to treat and prevent inherited retinal diseases for patients with conditions such as X-linked retinoschisis and Stargardt disease.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
GenSight Biologics
This company develops gene therapies for patients suffering from neurodegenerative retinal diseases and central nervous system disorders.
Nightstar
This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.
Restore Vision
This clinical-stage biotechnology company develops visual restoration gene therapies to treat blindness caused by genetic retinal disorders for patients with retinitis pigmentosa.
RhyGaze
This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.
Adverum Biotechnologies
The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.